Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Entera Bio (ENTX) Revenue (2019 - 2025)

Entera Bio has reported Revenue over the past 6 years, most recently at $42000.0 for Q1 2025.

  • For the quarter ending Q1 2025, Revenue changed N/A year-over-year to $42000.0, compared with a TTM value of $42000.0 through Dec 2025, down 76.8%, and an annual FY2025 reading of $42000.0, down 76.8% over the prior year.
  • Revenue came in at $42000.0 for Q1 2025, down from $82000.0 in the prior quarter.
  • In the past five years, Revenue ranged from a high of $165000.0 in Q4 2021 to a low of $8000.0 in Q3 2022.
  • Median Revenue over the past 4 years was $62500.0 (2022), compared with a mean of $77333.3.
  • The sharpest move saw Revenue soared 273.81% in 2021, then tumbled 94.29% in 2022.
  • Over 4 years, Revenue stood at $165000.0 in 2021, then tumbled by 91.52% to $14000.0 in 2022, then skyrocketed by 485.71% to $82000.0 in 2024, then plummeted by 48.78% to $42000.0 in 2025.
  • Per Business Quant, the three most recent readings for ENTX's Revenue are $42000.0 (Q1 2025), $82000.0 (Q4 2024), and $42000.0 (Q3 2024).